[Isoprodian in combination with ethambutol and rifampicin in the treatment of tuberculosis (author's transl)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011515:Prothionamide / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D004338:Drug Combinations; D013450:Sulfones; D011515:Prothionamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
Klinische Feldstudie über die Tuberkulosebehandlung mit Isoprodian in Kombination mit EMB-Fatol und anderen Antituberkulotika